FDA's Orthopedic and Rehabilitation Devices Panel voted 6-5 in favor of Medtronic's new Amplify spinal implant. The device is designed to stimulate bone growth in patients who have had spinal surgery. Last week FDA voiced concerns about the number of cancer cases seen among patients treated with the Amplify, which uses a protein called recombinant bone morphogenetic protein-2, or rhBMP-2, to promote bone growth. Although FDA is not required to follow the recommendation of the panel, it usually does.